Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Filings indexed 582 across all filing types
Latest filing 2023-01-06 Major Shareholding Noti…
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2023-01-06 English
8-K
Regulatory Filings
2023-01-03 English
FORM 4
Director's Dealing
2022-11-23 English
FORM 4
Director's Dealing
2022-11-14 English
FORM 4
Director's Dealing
2022-11-09 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.